Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 11:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 35,371 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: Sigmoidoscopy; Procedure
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 35 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Sport-related Concussion
Interventions: Screen Time Restriction (ST-Restricted), Aerobic Exercise (AE), Screen-time restricted plus aerobic exercise (STR+AE), Stretching Only; Behavioral
Lead sponsor: Children's Health; Other
Eligibility: 12 Years to 17 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Plano, Texas

Conditions: Bone Marrow Transplantation
Interventions: Ronacaleret (100mg tablet), Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: COVID-19
Interventions: CVXGA; Biological
Lead sponsor: CyanVac LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 227 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: San Diego, California • Boise, Idaho • Sioux City, Iowa + 7 more

Conditions: Inflammation
Interventions: Breakfast meal with placebo powder, Breakfast meal with 2 serving equivalents of blueberries, Breakfast meal with 4 serving equivalents of blueberries; Other
Lead sponsor: USDA, Western Human Nutrition Research Center; Federal
Eligibility: 18 Years to 60 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Davis, California

Conditions: Metastatic Neuroendocrine Prostate Cancer
Interventions: [68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB, [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB, L-Lysine HCl-L-Arginine HCl, 2.5 %,, Gonadotropin-releasing hormone (GnRH) analogues, GnRH antagonists, Antiemetics & antinauseants, Metoclopramide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Omaha, Nebraska • New York, New York

Conditions: Healthy Subjects
Interventions: Ziresovir, Placebo; Drug · Other
Lead sponsor: Shanghai Ark Biopharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Healthy
Interventions: Nifedipine Extended Release tablets 60 mg, single dose, ADALAT® CC Extended Release Tablets 60 mg; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid, Leukemia,Myeloid, Chronic
Interventions: Single Agent Asciminib, Low TKI, Elective Free Treatment; Drug · Combination Product · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 8
States / cities: Birmingham, Alabama • Atlanta, Georgia • Augusta, Georgia + 5 more

Conditions: Advanced Cancer, Pancreas Cancer, Pain
Interventions: Celiac Plexus Radiosurgery; Radiation
Lead sponsor: Dr. Yaacov Lawrence; Government
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: New York, New York • Columbus, Ohio

Conditions: Polyneuropathies, Wild Type ATTR Amyloidosis, Wild-Type Transthyretin-Related (ATTR)Amyloidosis, Wild-Type Transthyretin Cardiac Amyloidosis, Transthyretin Amyloidosis
Interventions: patisiran; Drug
Lead sponsor: Austin Neuromuscular Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Dental Malocclusion, Angle Class II, Angle Class I, Crowding, Tooth
Interventions: BRIUS; Device
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 10 Years to 17 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Sarcoma
Interventions: therapeutic conventional surgery, 3-dimensional conformal radiation therapy; Procedure · Radiation
Lead sponsor: European Organisation for Research and Treatment of Cancer - EORTC; Network
Eligibility: 18 Years to 120 Years
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: ALXN2050, Fluconazole, Rifampin; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Obesity
Interventions: Lifestyle intervention, Health education control, Individual, All Groups; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 21 Years to 75 Years
Enrollment: 631 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 14
States / cities: Bronson, Florida • Bunnell, Florida • Cross City, Florida + 11 more

Conditions: Placenta Accreta, Postpartum Hemorrhage, Cesarean Section, Tranexamic Acid
Interventions: Tranexamic Acid, Placebo Drug; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Fresno, California

Conditions: Obesity
Interventions: K-757 120 mg BID and K-833 100 mg BID, K-757 120 mg BID and matching placebo to K-833, Matching placebo to K-757 and matching placebo to K-833; Drug
Lead sponsor: TriGemX Bio, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 22
States / cities: San Diego, California • Stockbridge, Georgia • Topeka, Kansas + 19 more

Conditions: Depression
Interventions: Traditional Attention Bias Modification, Gamified Attention Bias Modification, Sham Attention Bias Modification; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 70 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency, Hyperlipoproteinemia Type 1
Interventions: Volanesorsen; Drug
Lead sponsor: Akcea Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 8
States / cities: Huntington Beach, California • San Francisco, California • Boca Raton, Florida + 5 more

Conditions: Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
Interventions: Atezolizumab Injection, Bevacizumab, Transarterial chemoembolization; Drug · Combination Product
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Multiple Myeloma
Interventions: Fluphenazine HCl; Drug
Lead sponsor: Immune Control; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania • San Antonio, Texas

Conditions: Ocular Hypertension, Open Angle Glaucoma
Interventions: BOL-303259-X, Timolol maleate; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 40 Years to 90 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Lung Cancer, Non-Small Cell
Interventions: Pazopanib (GW786034); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 13
States / cities: Scottsdale, Arizona • Fort Myers, Florida • Orlando, Florida + 10 more

Conditions: Major Depressive Disorder
Interventions: MoodGYM; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Microbiome-Mediated Gut Dysfunction in Non-Alcoholic Fatty Liver Disease

Concussion Screen Use Recovery Time

An Adaptive Phase I Study to Evaluate the Safety, Efficacy and Dose Responses of Ronacaleret in Healthy Human Volunteers

A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults

The Effects of Antioxidants in Blueberry Powder on Inflammation Induced by a Single High Fat Meal.

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects

A Relative Bioavailability Study of 60 mg Nifedipine ER Tablets Under Non-fasting Conditions

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

Celiac Plexus Radio-Surgery for Pain Management

Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy

BRIUS Vs FFA Efficiency

Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma

Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants

Rural Lifestyle Eating and Activity Program (Rural LEAP)

Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study

A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833

Confirmatory Efficacy Trial of Attention Bias Modification for Depression

The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome

Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma

BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer

Effectiveness and Acceptability of MoodGYM in Treating Depressive Symptoms in Chinese Americans